A new vaccines drug substance facility and R&D pilot plant, completed by the end of 2028, will create over 200 new jobs.

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell ...

GSK this morning said it had acquired an experimental therapy from Chimagen Biosciences that it aims to test in different forms of lupus, and possibly other autoimmune diseases. GSK paid $300 ...

GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.

Bearish flow noted in GSK (GSK) Pharma with 14,964 puts trading, or 17x expected. Most active are 11/1 weekly 37 puts and 11/1 weekly 38.5 calls, with total volume in those strikes near 19,700 ...

Welcome to today's call and webcast. The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to Slide 2. This is the usual safe harbor ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

Sustainalytics’ controversies research identifies companies involved in incidents and events that may negatively affect stakeholders, the environment or the company’s operations. Controversies are ...